EYEN - EYENOVIA, INC.
IEX Last Trade
0.0886
0.002 2.144%
Share volume: 15,870
Last Updated: Thu 26 Dec 2024 08:29:08 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$0.09
0.00
2.19%
Fundamental analysis
25%
Profitability
25%
Dept financing
5%
Liquidity
50%
Performance
23%
Performance
5 Days
1.30%
1 Month
-21.47%
3 Months
-81.51%
6 Months
-86.41%
1 Year
-95.68%
2 Year
-94.68%
Key data
Stock price
$0.09
DAY RANGE
$0.08 - $0.09
52 WEEK RANGE
$0.09 - $2.57
52 WEEK CHANGE
-$95.88
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Michael M. Rowe
Region: US
Website: eyenovia.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: eyenovia.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Eyenovia, Inc. engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. Its product candidates include MicroLine, MicroPine and MydCombi.
Recent news